Veradermics (MANE) Shares Outstanding (2024 - 2026)
Veradermics' (MANE) quarterly Shares Outstanding (Entity) came in at $22.7 million in Q1 2026, up 2980.89% YoY from $736933.0 in Q1 2025, and up 2928.19% on a QoQ basis from $749760.0 in Q4 2025.
Veradermics (MANE) Shares Outstanding (2024 - 2026) Analysis & Trends
Veradermics (MANE) has 3 years of Shares Outstanding (Entity) data on file, last reported at $22.7 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 2980.89% year-over-year to $22.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.7 million (up 2980.89% YoY) and the FY2025 annual result came in at $749760.0, up 1.74% from the prior year.
- Shares Outstanding (Entity) climbed to $22.7 million in Q1 2026, from $749760.0 in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $22.7 million in Q1 2026 to a low of $736933.0 in Q4 2024.
- A 3-year average of $6.2 million and a median of $743346.5 in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2025 — Shares Outstanding (Entity) advanced 1.74% — and 2026, when it surged 2980.89%.
- Tracing MANE's Shares Outstanding (Entity) over 3 years: stood at $736933.0 in 2024, then increased by 1.74% to $749760.0 in 2025, then jumped by 2928.19% to $22.7 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $22.7 million (Q1 2026), $749760.0 (Q4 2025), and $736933.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Veradermics | 4.70 Bn | 4.70 Bn | - | 40.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.44 Mn |
| Mar 31, 2026 | 22.70 Mn |
| Dec 31, 2025 | 744,991.00 |
| Mar 31, 2025 | 736,933.00 |
| Dec 31, 2024 | 736,933.00 |